RPAY vs. PHR, TTGT, RDWR, ACCD, CATM, WU, ALIT, CNXC, CBZ, and ENV
Should you be buying Repay stock or one of its competitors? The main competitors of Repay include Phreesia (PHR), TechTarget (TTGT), Radware (RDWR), Accolade (ACCD), Cardtronics (CATM), Western Union (WU), Alight (ALIT), Concentrix (CNXC), CBIZ (CBZ), and Envestnet (ENV).
Phreesia (NYSE:PHR) and Repay (NASDAQ:RPAY) are both small-cap medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, analyst recommendations, earnings, valuation, risk, community ranking, profitability and dividends.
Repay has a net margin of -29.49% compared to Repay's net margin of -31.87%. Phreesia's return on equity of 7.74% beat Repay's return on equity.
Phreesia has a beta of 0.92, suggesting that its stock price is 8% less volatile than the S&P 500. Comparatively, Repay has a beta of 1.39, suggesting that its stock price is 39% more volatile than the S&P 500.
92.1% of Phreesia shares are owned by institutional investors. Comparatively, 82.7% of Repay shares are owned by institutional investors. 5.8% of Phreesia shares are owned by insiders. Comparatively, 11.0% of Repay shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.
In the previous week, Repay had 1 more articles in the media than Phreesia. MarketBeat recorded 4 mentions for Repay and 3 mentions for Phreesia. Phreesia's average media sentiment score of 1.02 beat Repay's score of 0.29 indicating that Repay is being referred to more favorably in the news media.
Repay has lower revenue, but higher earnings than Phreesia. Repay is trading at a lower price-to-earnings ratio than Phreesia, indicating that it is currently the more affordable of the two stocks.
Phreesia currently has a consensus target price of $30.92, suggesting a potential upside of 60.56%. Repay has a consensus target price of $10.50, suggesting a potential downside of 3.14%. Given Repay's stronger consensus rating and higher possible upside, equities analysts clearly believe Phreesia is more favorable than Repay.
Phreesia received 34 more outperform votes than Repay when rated by MarketBeat users. Likewise, 65.64% of users gave Phreesia an outperform vote while only 61.44% of users gave Repay an outperform vote.
Summary
Repay beats Phreesia on 10 of the 18 factors compared between the two stocks.
Get Repay News Delivered to You Automatically
Sign up to receive the latest news and ratings for RPAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RPAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
